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Vascular complicationsAbstract Objective: This study was performed to evaluate the safety and efﬁcacy of a locally
designed assiut femoral compression device (AFCD) versus manual compression (MC).
Background: Femoral compression devices have been developed thorough the past decades
without being strongly implemented in the catheterization laboratory. Their limited adoption
reﬂects concerns of high cost and conﬂicting data regarding their safety.
Patients and methods: This was a prospective study. We enrolled 206 consecutive patients under-
going diagnostic coronary angiography From July, 2012 to April, 2013. They were divided into
two groups: 100 patients used AFCD and 106 patients used MC for arterial hemostasis.
Results: Both groups were comparable regarding baseline characteristics. Concerning the primary
effectiveness end point, there was no difference in the mean time-to-hemostasis with AFCD
(12.5 ± 3 min) vs. MC (13 ± 2 min, p= 0.4). As regards safety, none of our research population
experienced major adverse events. No complication was new or unanticipated, and the type of com-
plication did not differ between the two groups. The incidence of vagal episodes were comparable
between both groups (3 patients (3%) in AFCD vs. 2 patients in MC (1.8%); p= 0.2). The use of
AFCD was associated with similar occurrence of minor complications, mainly ecchymosis and ooz-
ing, compared with MC (27% vs. 27.4%, p= 0.8). Large hematoma >5 cm was noted only in 1
patients (1%) in the AFCD arm vs. 2 patients (1.8%) in the MC arm (p= 0.8).
Conclusion: Our results indicate that AFCD is a simple, safe and effective alternative to MC for
hemostasis following diagnostic coronary angiography.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
The femoral approach is commonly used to obtain arterial ac-
cess in coronary angiography. Hemostasis is usually obtained
by manual compression (MC) after sheath removal. Vascular
access site complications result in signiﬁcant morbidity after
Figure 1 Device design. (1) Black fabric belt with a plastic
fastener and an elongation kit. (2) Plexiglass arch. (3) Metallic
screw. (4) Reusable pressure dome.
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16.8% of cases.1–4 The rates of these complications depend on
the operator’s experience, the type of intervention attempted,
the introducer size and primarily, on the duration of the MC.5
Even though femoral compression devices (FCD) are being
introduced into the market since decades, they are not strongly
implemented due to their higher cost without showing remark-
able superiority in the safety or efﬁcacy comparedwith theMC.6
At Assiut University Hospitals, we use only conventional
MC to achieve hemostasis. Currently, with the increase in pa-
tient numbers done per day; ﬁnding an alternative to MC with-
out increasing procedural complications or price is mandatory.
For this reason, we collaborated with the Mechatronic Engi-
neering Department, to develop a locally designed compres-
sion device.
At this early stage, we are reporting the safety and efﬁcacy
of this new assiut femoral compression device (AFCD) com-
pared to conventional MC for femoral artery access site
hemostasis after diagnostic coronary angiography.
2. Methods
2.1. Study design and patients selection
We performed a non-randomized, parallel assignment, prospec-
tive study at the catheterization laboratory of the Assiut Uni-
versity Hospitals. Patients between 18 and 85 years of age,
scheduled to undergo a diagnostic coronary procedure via arte-
rial puncture of common femoral artery were eligible for enroll-
ment in the study. Patients were excluded from the study if they
required Percutaneous Coronary Intervention (PCI) following
coronary angiography, or if the patient has any mental illness,
heart failure III/IV grades, or aged <18 years.
2.2. Study groups and protocol
From July, 2012 to April, 2013, 206 consecutive patients that
fulﬁlled the inclusion criteria were enrolled in this study. They
were divided into two groups: 100 patients used AFCD and
106 patients used conventional MC for arterial hemostasis.
The study protocol was reviewed and approved by the institu-
tional review committee, and all patients granted their in-
formed consent to be included in the study.
The demographic and clinical data were prospectively col-
lected using a standardized ‘‘procedural datasheet’’ and the
data were recorded on the day of the procedure, or at the time
when the complications were noted.
All patients received a standard 2500 IU heparin in the
sheath pre-procedural. The conventional compression therapy
consisted of MC at the femoral access site immediately at the
end of the diagnostic catheterization procedure for 10–15 min.
Ambulation was normally initiated 4 h after complete hemos-
tasis according to our local protocols.
All patients were scheduled to undergo a clinical assessment
of the femoral access site the day after the procedure for any
evidence of complications.
2.3. Device description
Assiut Femoral Compression Devices (AFCD) is a femoral com-
pression system, made of plexiglass, consisting of an arch witha reusable pressure dome connected with a metallic screw and
a belt (Fig. 1). The pressure dome is situated over the vessel
puncture site in the groin. The belt is placed around the patient
and the dome applies a mechanical pressure over the vessel
puncture site to induce hemostasis. The pressure of the dome
is controlled by the assessment of distal pulse. The arch and
the belt provide counter pressure for the dome. Sterile dispos-
able gloves are positioned over the dome to prevent its contact
with blood. The duration of compression should be 10–15 min
with looking for dorsalis pedis pulsation and cyanosis of the
limb. Instruction is to keep compression with no palpable dor-
salis pedis pulsations for 2–5 min safely, then to release partly
till the pulse is felt and to continue compression till 10–15 min
is completed.
2.4. Study end points
2.4.1. The primary efﬁcacy end point of the study was time-to-
hemostasis (TTH), measured in minutes
Hemostasis was deﬁned as no or minimal subcutaneous oozing
and the absence of expanding or developing hematoma.7 TTH
was measured from the time the introducer sheath was re-
moved to the time hemostasis was achieved. The entry site
was revised for signs of active bleeding (acknowledged as fail-
ure of closure strategy). In the case of failure, the compression
was restored manually for additional 2–5 min and observed
thereafter until bleeding stops.
Figure 2 Flow of patients through the study. AFCD= assiut
femoral compression device.
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1. Device success: This was deﬁned as easy application of the
device with good ﬁxation and stability and achieving ﬁnal
hemostasis. Device stability was deﬁned as absence of tilt
and/or mobility after application of the device on top of
the patient’s groin. Assessment of the device application
was performed using a questionnaire with a scale of three
grades; ‘‘Easy’’, ‘‘Difﬁcult’’ and ‘‘Requires Improvement’’.
Assessment of stability and ﬁxation of the device was per-
formed on a scale deﬁned as ‘‘Very Good’’, ‘‘Good’’ and
‘‘Bad’’.
2. Procedure success: This was deﬁned as hemostasis achieved
by the assigned method, without the occurrence of a clo-
sure-related major adverse event (MAE). MAE was deﬁned
as symptomatic bleeding associated with hemoglobin drop
P5 g/dL requiring blood transfusion, fatal bleeding that
directly results in death, a pseudoaneurysm or arteriove-
nous ﬁstula, distal arterial embolism, infections requiring
administration of IV antibiotics or debridement, and the
need for vascular surgery.7,8
2.4.3. The primary safety end point was deﬁned as the absence of
MAE on discharge
2.4.3.1. The secondary safety end points included.
1. Minor complications: Any oozing (leakage of blood from
the puncture site requiring digital pressure), ecchymosis
(bleeding into subcutaneous tissue planes causing bluish-
purple discoloration >4 cm in diameter), hematoma (non
pulsatile mass >1 cm in diameter), and infections treatable
with oral antibiotics.8,9
2. Patient discomfort was assessed based on a short form of
the McGill Pain Questionnaire using a Present Pain Inten-
sity (PPI) scale that rated pain from 0 (no pain) to 5
(excruciating).8
3. Vasovagal manifestations (sweating, bradycardia, nausea
and vomiting) were recorded.
2.5. Sample size calculation
The study was designed to have an 80% power to detect a
2 min difference in time-to-hemostasis (TTH) with an overall
type I error rate of 0.05 (two sided). Sample size calculated
to be at least 99 patients in each arm. Mean TTH was esti-
mated to be 15 min in the AFCD group and 13 min in the
MC group with a common standard deviation (sigma) of
5 min.102.6. Statistical analysis
Categorical data were presented as counts and proportions
(percentages) and compared by Pearson chi-square analysis
or Fischer’s exact test if the expected cell count for a 2 · 2 table
was <5. Normal distribution of continuous data was tested
using the Kolmogorov–Smirnov test. Continuous and nor-
mally distributed data are presented as mean ± 1 standard
deviation and were compared by two-tailed unpaired t-test.
These comparisons were performed using the SPSS version16.0 software package (SPSS Inc., Chicago, IL), and a p value
of 60.05 was considered to be signiﬁcant.
3. Results
3.1. Patients characteristics
The study population consists of 206 patients who underwent
diagnostic coronary procedure via arterial puncture of the
common femoral artery. These patients were divided into
two groups: 100 patients used AFCD and 106 patients used
MC for arterial hemostasis (Fig. 2). The baseline demographic
and clinical characteristics of the two study groups are summa-
rized in Table 1. The two groups were comparable with no sig-
niﬁcant differences in baseline characteristics.
Approximately three-quarters of patients in each group
were men. The body mass index was >30 kg/m2 in 36% and
30% of patients in the AFCD and MC groups, respectively
(p=NS).
3.2. Analysis of efﬁcacy
Concerning the primary effectiveness end point, the mean
TTH was 12.5 ± 3 min in the AFCD group vs. 13 ± 2 min
in the MC group, with no signiﬁcant difference between the
two groups (p= 0.4) (Fig. 3).
The procedure success was observed in 95 patients of the
AFCD group and all patients of the MC group. None of our
research population experienced a MAE.
The device success was observed in 90 patients of the
AFCD group. Ten patients experienced device failure
(Fig. 4). Five of them had a difﬁcult application process but
ultimately good hemostasis. The remaining 5 patients crossed
over to MC without further vascular complication because
of a device failure. In one patient, inadequate hemostasis
was associated with a device malfunction in the form of sudden
break of the belt fastener due to marked stretch of the belt
around an overweight patient. The remaining four cases were
associated with in-appropriate positioning of the belt under
the patient that resulted in instability of the dome with tilting
of the AFCD and ineffective compression.
3.3. Regarding safety
No complication was new or unanticipated, and the type of
complication did not differ between the two study arms. None
of our study population reported any MAE.
Some secondary adverse events occurred in each study
group, without statistically signiﬁcant differences among the
Table 1 Baseline characteristics of the study population.
Variable MC (N= 106) AFCD (N= 100) P
Age (years) 55 ± 16 52 ± 10 NS
Male gender n (%) 75 (70.7%) 76 (76%) NS
Smoking n (%) 31 (29.2%) 37 (37%) NS
Hypertension n (%) 46 (43.4%) 51 (51%) NS
IHD n (%) 70 (66%) 60 (60%) NS
Dyslipidemia n (%) 30 (28.3%) 31 (31%) NS
Diabetes mellitus n (%) 34 (32%) 35 (35%) NS
Body mass index n (%)
From 18.5 to 25 kg/m2 37 (35%) 31 (31%) NS
From 25 to 30 kg/m2 37 (35%) 33 (33%)
>30 kg/m2 32 (30%) 36 (36%)
Previous femoral puncture 8 (7.5%) 6 (6%) NS
INR impaired n (%) 2(1.8%) 4(4%) NS
Warfarin before hospital admission 5 (4.7%) 4 (4%) NS
Chronic aspirin therapy 90 (84.9%) 96 (96%) NS
Chronic clopidogrel therapy 33 (31.1%) 30 (30%) NS
Data are presented as mean ± standard deviation, number (%) of patients. MC=manual compression; AFCD= assiut femoral compression
device; IHD= ischemic heart disease; NS = not signiﬁcant.
Figure 3 Primary effectiveness endpoint: time-to-hemostasis in
the AFCD group compared to those with MC. Time-to-hemos-
tasis showed no signiﬁcant difference between the two groups
(p=NS). MC= manual compression; AFCD= assiut femoral
compression device.
236 A.K.M. Hassan et al.groups (Fig. 5). The overall incidence of minor complications
was 27.4% (29 patients) in the MC group and 27% (26
patients) in the AFCD group with no statistically signiﬁcantFigure 4 Secondary effectiveness end points: devicdifference between them (Table 2). These minor complications
were mainly ecchymosis and oozing in both groups. Large
hematoma >5 cm was noted in 2 pts. (1.8%) in MC arm vs.
1 pt. (1%) in AFCD arm (p= 0.8).
3.4. Regarding pain
The median and mean scores of pain assessment scale for each
group is presented in Table 2. Patients did not report a signif-
icant difference in the pain score in the AFCD group com-
pared with MC group (p=NS). None of the closure
procedures using AFCD was aborted because of pain at the ac-
cess site. The incidence of vagal episodes was comparable be-
tween both groups (2 pts. in MC (1.8%) and 3 pts. (3%) in
AFCD; p= 0.2) (Table 2).4. Discussion
In this prospective study of a new locally developed femoral
compression device, we could demonstrate a high procedural
success rate, with no signiﬁcant difference in the mean time-
to-hemostasis, nor complication rate compared to MC.e success and failure ﬂow chart. Pt. = patients.
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ing that AFCD is a simple, safe and effective alternative
to MC for hemostasis following diagnostic coronary
angiography.
Few large studies have compared vascular access strategies
in patients undergoing elective coronary procedures.6,11,12 Sev-
eral devices have been developed to aid in the closure of the
femoral arteriotomy, including, extravascular plug devices
(VasoSeal, AngioSeal, ExoSeal),7,13 percutaneous suture clo-
sure devices (Perclose, StarClose),14 and mechanical compres-
sion devices.15–19 Mechanical compression devices most
commonly used are the C-clamp or Compressor (Advanced
Vascular Dynamics, Portland, OR) and pneumatic FemoStop
device (Radi Medical Systems, Uppsala, Sweden). The C-
clamp compression device was ﬁrst introduced in 1974 and
functions much like a C-clamp used in carpentry.15–19 TheFigure 5 Percent of complications in the study group. MC= man
Table 2 Effectiveness and safety results in the study groups.
Parameter MC (N= 106)
Time-to-hemostasis (min ± SD) 13 ± 2
Pain grade (median (mean ± SD)) 2 (2.57 ± 0.6)
Vagal episodes 2 (1.8%)
Hematoma <5 cm 5 (4.7%)
Hematoma >5 cm 2 (1.8%)
Ecchymosis 15 (14.1%)
Oozing 7 (6.6%)
Peripheral ischemia 0
Retroperitoneal hematoma 0
Pseudo aneurysm 0
AV ﬁstulae/bruit 0
Site infection 0
Minor complications 29 (27.4%)
Major adverse events 0
Data are presented as mean ± standard deviation, number (%) of patien
compression device; AV = arterio-venous; NS = not signiﬁcant.pneumatic FemoStop device consists of a belt positioned under
the patient’s hips that holds a plastic arch bar over the groin.
On one side of the bar, there is a clear soft dome that can be
inﬂated using a hand-held manometer. Compression to the
femoral artery site occurs via the pressure exerted by the in-
ﬂated dome.15–17,19 All these devices including our AFCD pro-
vide the application of constant pressure while maintaining
limb perfusion monitored by only one nurse and free up the
operator. However, increased cost per patient of both Femo-
stop (75–150 $) and C-clamp (50–100 $) compared with MC
was identiﬁed as a disadvantage.15,19 Our AFCD total cost is
around 15 $ once.
The C-clamp and Femostop devices were compared to MC
in a number of studies,15–17,19 which generally reported equal
efﬁcacy with no signiﬁcant differences regarding femoral vas-
cular complication rates.ual compression; AFCD= assiut femoral compression device.
AFCD (N= 100) P
12.5 ± 3 NS
2 (2.56 ± 0.83) NS
3 (3%) NS
4 (4%) NS
1 (1%) NS
13 (13%) NS
8 (8%) NS
0
0
0
0
0
26 (26%) NS
0 –
ts or median. MC=manual compression; AFCD= assiut femoral
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hemostasis, our study showed equal efﬁcacy that is presented
as equivalent mean TTH between AFCD and MC (12.5 ± 3
vs. 13 ± 2 min), in accordance with Lehmann et al.20 who
demonstrated that TTH was 13.9 ± 3.5 min for MC and
14.5 ± 4.5 min for C-clamp and 15.6 ± 4.81 min for Femo-
stop device. Also Bogart19 demonstrated that mean TTH
was 22 min for MC and 31 min for mechanical device com-
pression. On the other hand, Walker et al.15 showed that
TTH was much shorter in the MC group (12.9 min) than the
Femostop group (35.2 min). This can be explained by the dif-
ference in the study design, where Femostop application proto-
col was extended for 30 min.
Device failure rate in our study was 10%, which was in
agreement with Femostop device failure rate.15,21 Bogart19 re-
ported that 13% of cases with compressor device was switched
to MC which is an accepted failure rate.
Concerning patient comfort, the pain level at the time of
sheath removal did not differ signiﬁcantly between our AFCD
groups compared with the MC group. This was in agreement
with Benson et al.22 who reported that the mean pain level
in the MC group was 1.9 ± 0.5 while in the Compressor group
it was 2.1 ± 0.5. On the other hand, Norderhaug et al.15
showed that there was more discomfort with the Femostop de-
vice than with the MC as the device application was for 1 hour
in all coronary angiography patients compared to 12 min for
MC. Also, Lehmann et al.20 presented that there was more dis-
comfort with femostop use (3.1 ± 2.1) compared with MC
(1.9 ± 1.9) or C-clamp (2.2 ± 2.0) (p< 0.001).
Conﬂicting results were also noted regarding safety issue.
Sridher et al. showed a lower complication rate in the Femo-
stop device group compared with MC group.22 Also Beres
et al.15 agreed with this ﬁnding. On the other hand, Lehmann
et al.20 concluded that the use of the Femostop device leads to
longer compression times, greater discomfort, more bleeding,
and larger hematomas.
In our study, no complication was new or unanticipated.
Neither the type nor the incidence of complication differs be-
tween the two groups. None of our study population reported
any MAE. The incidence of hematoma was 5% in AFCD
group vs. 6.5% in the MC group in accordance with Lehmann
et al.20 who showed that the frequency of hematoma formation
was statistically similar between MC (10%) and mechanical
compression (11% for C-clamp and 13% for Femostop). How-
ever, Walker et al. showed that prevalence of hematoma was
higher in the Femostop group (18.1%) than the MC group
(9.1%). On the other hand, Norderhaug et al.15 showed that
the prevalence of hematoma was less in the Femostop group
7% vs. 11% in the MC group. Also, Semler17 reported that
the incidence of hematoma was 2% using the Compressor
compared with 6% for MC.
Our study represents a similar incidence of ecchymosis be-
tween MC (14%) and AFCD (13%) in accordance with Leh-
mann et al.20 who showed that the frequency of ecchymosis
formation was statistically similar between MC (38%) and
mechanical compression (34% for C-clamp and 29% for
Femostop).
The results of this study signify oozing frequency to be sta-
tistically similar between MC (6.6%) and AFCD (8%) in
accordance with Lehmann et al.20 that represent similar bleed-
ing rate between MC (8%) and mechanical compression (6%
for C-clamp and 12% for Femostop). On the other hand,Benson et al.22 showed more signiﬁcant rebleeding 7/61
(11%) in mechanical compression compared to zero/30 in
the MC group, which can be attributed to the lack of clear def-
inition of rebleeding in the MC group.
This study had several limitations; the application of
AFCD was not randomly assigned between the study groups;
however the results regarding efﬁcacy and complications were
reported prospectively by the resident doing the compression
using a standardized ‘‘procedural datasheet’’. The nature of
the study precluded blinding of treatment strategy for either
patient or treating physician, though most outcomes were eval-
uated without knowledge of the assigned technique. Further-
more, cost-effectiveness has not been examined in this study,
however, it is well known that the locally developed device
costs much less than any commercially available one. Finally,
improvement of device belt with removal of the fastener clip is
a point for improvement in the device for further applications.
5. Conclusions
Our results indicate that AFCD is a simple, safe and effective
alternative to MC for hemostasis following diagnostic coro-
nary angiography.
Future prospective
Next step is to use AFCD in more complicated patients
undergoing PCI. Aim is to reduce time of post-procedural
recumbence form 12–14 h. with MC to 4–6 h. with the AFCD.
This will reduce expenses of the procedure and reduce hospital
stay.Conﬂict of interest
We have no conﬂict of interest to declare.References
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